Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma
- 28 February 2017
- journal article
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 8 (3) , 165-169
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialJournal of Clinical Oncology, 2016
- Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaBlood, 2016
- Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensJournal of Clinical Oncology, 2015
- How I treat fragile myeloma patientsBlood, 2015
- Curing myeloma at last: defining criteria and providing the evidenceBlood, 2014
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood, 2011
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled TrialJournal of Clinical Oncology, 2010
- Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the ClinicMayo Clinic Proceedings, 2010
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing NationJournal of Clinical Oncology, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008